semaglutide in patients with T2D were assessed in the SUSTAIN clinical trial programme, in which semaglutide provided superior improvements in glycated haemoglobin (HbA1c) and body weight vs comparators, and furthermore showed CV risk reduction in SUSTAIN 6, a 2-year pre-approval CV outcomes trial. 1, 2 In SUSTAIN 6, semaglutide was associated with a higher rate of diabetic retinopathy (DR) complications. 2 DR complications were an adjudicated composite secondary endpoint, based on time from randomization to the first occurrence of need for retinal photocoagulation or treatment with intravitreal agents, diagnosis of vitreous haemorrhage, or onset of diabetes-related blindness. Unlike most phase III T2D trials, in SUSTAIN 6, patients with advanced diabetes and high risk of CV disease were included, with no upper limit on HbA1c. 2 A recently published paper from SUSTAIN 6 concludes that early worsening of DR is a known phenomenon associated with the rapidity and magnitude of improvement in glycaemic control with insulin, and the DR findings in SUSTAIN 6 are consistent with this. 3 The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein coupled receptor (GPCR) that shows high homology among spe-
cies. Detection of GPCRs by immunohistochemistry (IHC) is
technically difficult and many antibodies have been shown to be unspecific. 4 
| Immunohistochemistry and immunofluorescence
Sections ( 
| In situ hybridization
Single and duplex ISH were performed with the RNAscope 2. 3 | RESULTS
| GLP-1R expression in normal human eyes
In normal human eyes (n = 4), GLP-1Rs were detected in single cells in the retinal GCL ( Figure 1A ). GLP-1Rs were not detected in the reti- Figure S1C ).
| GLP-1R expression in PDR
The expression of GLP-1Rs was studied in eye sections from patients confer neuroprotection in DR. 16 As animal models should always be interpreted with caution, it is likely that studies in other animal models reflecting other aspects of DR would be needed for a full understanding of the potential of GLP-1RAs in DR. 17 A DR outcome study in patients with type 2 diabetes will be conducted with semaglutide.
Neither GLP-1R protein nor mRNA was detected in eye sections from patients with advanced stages of PDR. Importantly, we did not detect any signs of GLP-1R expression in areas characterized by neovascularization. The lack of GLP-1R expression in the GCL may be Other studies using rodent animal models reflecting early diabetic eye disease have suggested that GLP-1RAs could prevent the occurrence of DR, and show GLP-1R expression in the retina, in the GCL, inner nuclear layer and outer nuclear layer 16 ; however, the GLP-1R expression methodology applied in those studies with IHC is not valid because they used antibody ab39072, which has been withdrawn from the market as a result of a confirmed lack of specificity. 9 With the limited GLP-1R expression and the confinement to neurons in GCL in normal human eyes it can be hypothesized that GLP-1RAs are unlikely to play a direct role via the GLP-1R in the worsening of established DR.
The present data are in contrast to the literature suggesting more abundant retinal expression of GLP-1Rs. 16 In the present study, we In conclusion, GLP-1Rs are rarely expressed in the normal human eye and appear undetectable in advanced stages of PDR.
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